Sanofi (SNY) halts shipments of cholesterol drug Praluent developed with Regeneron (REGN) due to availability issues. Read ...

Sanofi (NASDAQ:SNY) announced on Tuesday that it has stopped supplying Praluent in China due to limited availability of the popular cholesterol medication.

Sanofi said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French ...

Sanofi is pulling its PCSK9 drug Praluent from the Chinese market. President Donald Trump said U.S. pharmaceutical tariffs ...

Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases. Valued at $61.8 billion by ...

Your Good Health: Praluent lessens the chance of a heart attack in woman with FH FH is a genetic condition of very high cholesterol levels that presents a high risk for coronary artery disease.

If the diagnosis of FH is certain, I advise you to continue taking Praluent, as it is likely to have a very large improvement in your chances of getting a heart attack.

If the diagnosis of FH is certain, I advise you to continue taking Praluent, as it is likely to have a very large improvement in your chances of getting a heart attack. There are a variety of programs ...

The dosage of Praluent for pediatric patients aged 8 years and older with HeFH is based on body weight and can be adjusted based on LDL-C lowering response.

Approval extends treatment of Praluent to children aged 8 and older with heterozygous familial hypercholesterolemia (HeFH)TARRYTOWN, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, ...